title: [Clinical study on mometasone furoate nasal spray in the treatment of non-allergic rhinitis].
abstract: OBJECTIVE
  To evaluate the outcome of mometasone furoate nasal spray (MFNS) used for 3 months on non-allergic rhinitis (NAR).
  
  
  METHODS
  In this multicenter study, NAR patients were enrolled from eight hospitals and received MFNS 200 microgram once daily for 3 months. The patients were followed-up for three times (at baseline, month 1 and month 3) to record the symptom scores and nasal endoscopic appearances. At the same time, the adverse events frequency was recorded and analyzed.
  
  
  RESULTS
  A total of 188 NAR cases were enrolled in the study. The total nasal symptom score assessment descended significantly at month 1 (1.70 ± 0.75) and month 3 (0.95 ± 0.79) visits versus at baseline (2.67 ± 0.68, Z value were from -11.603 to -10.491, all P < 0.01). The individual symptoms, including nasal stuffiness, nasal discharge, nasal stuffiness-related dizziness or headache, hyposmia, sleep quality, daily life activity, work or study efficiency, mental status, and whole body fatigue, also showed less scores at month 1 and month 3 visits versus at baseline (Z value were from -11.313 to -6.802, all P < 0.01). At the same time, nasal mucosal appearances assessed by endoscopy had lower scores at month 1 (1.40 ± 0.62) and month 3 (0.75 ± 0.71) visits versus at baseline (2.27 ± 0.73, Z value were from -11.484 to -10.002, all P < 0.01). Additionally, adverse events were only observed in 5.3% cases with light rhinorrhagia and nasal dryness. No other side effect was found.
  
  
  CONCLUSIONS
  A 3-months administration of intranasal mometasone can effectively and safely improve NAR patients' clinical symptom and nasal mucosal appearances.
authors.affiliation: SUN Yat-sen University, Guangzhou 510080, China.
authors.forename: Ke-jun
authors.initials: KJ
authors.lastname: Zuo
authors.forename: Giyab A
authors.initials: GA
authors.lastname: Sail
authors.forename: Geng
authors.initials: G
authors.lastname: Xu
authors.forename: Zhen
authors.initials: Z
authors.lastname: Dong
authors.forename: Luo
authors.initials: L
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Shi
authors.forename: De-hui
authors.initials: DH
authors.lastname: Wang
authors.forename: Jian-yun
authors.initials: JY
authors.lastname: Xiao
authors.forename: Qiu-hang
authors.initials: QH
authors.lastname: Zhang
authors.forename: Xue-yuan
authors.initials: XY
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D059085:Nasal Sprays; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D012220:Rhinitis / Q000145:classification / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D059085:Nasal Sprays; D011244:Pregnadienediols; D000068656:Mometasone Furoate